VKORC1 — Drug Target

All drugs that target VKORC1 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Vitamin K antagonist

Phase 3 pipeline (2)

• INR101 · Yunhe Pharmaceutical (Tianjin) Co., Ltd · Vitamin K antagonist · Cardiovascular
  INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors.
• Vitamin K antagonists (VKA) · Population Health Research Institute · Vitamin K antagonist · Cardiovascular
  Vitamin K antagonists inhibit the vitamin K-dependent gamma-carboxylation of clotting factors, leading to anticoagulation.